{
  "title": "Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer",
  "url": "https://ascopubs.org/doi/10.1200/OA-25-00051",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: 67% of patients completed assessments, reducing discontinuation risk by 30%, enhancing clinical trial data quality."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN [SHIP NOW]**: Implement automated ePRO reminders at key intervals to improve patient engagement and compliance."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL [ðŸ”´ URGENT]**: Upcoming FDA regulations may require PRO integration in trials, emphasizing the need for robust ePRO solutions now."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: Self-selection bias could skew results toward healthier patients, potentially affecting the clinical validity of PROs."
    }
  ],
  "model": "granite4:tiny-h"
}